QuartzBio Snaps up SolveBio to Expand SaaS Data Management Capabilities for Clinical R&D
By Alex Keown
February 14, 2023
QuartzBio, a division of clinical research services organization Precision for Medicine, acquired SolveBio and its intelligent technologies and enterprise data management platform to help pharmaceutical and biotech companies manage sample and biomarker data across their entire portfolio.
The SolveBio technology platform will be integrated into QuartzBio’s suite of SaaS solutions. The addition of the SolveBio platform will provide Frederick, Maryland-based QuartzBio with a single, scalable solution that will support the company’s clinical sample inventory and biomarker data management operations for biopharma clients. The combined capabilities of both companies will create synergies between translational researchers and clinical operators.
According to QuartzBio, its end-to-end SaaS solutions provide “seamless monitoring and tracking of clinical sample status,” as well as ICF tracking and management of biomarker data. The platform not only generates scientific and operational insights while studies are in progress but also after they are completed. In all, the SaaS technology creates a fully connected data ecosystem that supports drug development programs. The addition of SolveBio’s technology platform only amplifies those capabilities.
Scott Marshall, general manager of QuartzBio, said SolveBio’s platform solution provides the company with an opportunity to bolster its current enterprise data management capabilities. He said the company’s enterprise Biomarker Data Management platform will allow teams to “efficiently acquire, integrate and harmonize/standardize data using scalable solutions” that are capable of being deployed across an entire portfolio. This will allow sponsors to build and access quality data assets that are needed to develop life-changing therapies.
“We knew that bringing on SolveBio’s platform technology and team would immediately amplify our capabilities and expand the use cases we can support to help pharmaceutical and biotech companies manage sample and biomarker data across their entire portfolio,” Marshall said. “The combined product offering positions us to be the central data platform to support translational research efforts, allowing for efficient integrations with upstream systems and layering in of advanced capabilities around insight generation to support the full complement of use cases we see in today’s diverse data ecosystems.”
Marshall noted that in many companies, sample and biomarker data is siloed. That means that R&D teams have to work with multiple vendors to manage the data streams across different labs and repositories. That can cause a significant slowdown in work. By combining the core technology capabilities of both companies, Marshall said it will create efficient workflows that “use high-quality and accurate data to inform decision-making and ultimately accelerating the drug development lifecycle.”
The combined technologies are agnostic to data modalities, added Tobi Guennel, senior vice president and chief architect at QuartzBio. The platforms support a full range of modalities, from high throughput to high content data. It also supports integration of real world data. Guennel said the platform offers a “library of configurable workflows” that will enable companies to seamlessly deploy new and edit existing data processing pipelines.
“We consistently hear and observe that biotech and pharmaceutical companies are focused on more effectively leveraging data across their enterprise to advance a variety of efforts… we are excited because we believe our suite of solutions fits in this data ecosystem. A key focus of our mission is to provide organizations with data-enabling technologies, with a laser focus on the space of sample and biomarker data management,” Marshall said.
Much like the technology platforms, the SolveBio team has seamlessly integrated into the QuartzBio team, Marshall said. SolveBio’s talent add will bolster product development efforts and amplify the QuartzBio team’s expertise levels, he added.
In a brief statement, David Caplan, SolveBio’s co-founder and chief technology officer, said the merger of the two teams and technologies will enable the organization to offer a comprehensive solution that enables the development of precision treatments.
- About the Author
- Latest Posts
Alex Keown is a freelance journalist who writes about a variety of subjects including the pharma, biotech, and life science industries. Prior to freelancing, Alex has served as a staff writer and editor for several publications.
